Satya Medicherla

Precision Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index868citations23works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

TGF-β signaling in diseases(5), Multiple Myeloma Research and Treatments(3), Metabolism, Diabetes, and Cancer(3), Cancer Mechanisms and Therapy(3), Kruppel-like factors research(2)

Publications23 total

UNI‐494 treatment improves measures of renal dysfunction and cardiac pathology in male rats receiving L‐NAME and angiotensin II
Physiological Reports·2025Open Access
Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats
Kidney360·2025Open Access
Intravenous UNI-494 Slows the Progression or Halts/Reverses AKI When Administered after Ischemia-Reperfusion in Rats
Journal of the American Society of Nephrology·2024
Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats
Journal of the American Society of Nephrology·2024
#604 Oral administration of UNI-494 ameliorates acute kidney injury in a rat model of delayed graft function
Nephrology Dialysis Transplantation·2024Open Access
#313 Enhanced urinary phosphorous reduction: comparative study of oxylanthanum carbonate and tenapanor in rat
Nephrology Dialysis Transplantation·2024Open Access
From <i>in silico</i> to <i>in Vitro</i> to <i>In Vivo</i>: Increasing Megakaryocytes to Treat Thrombocytopenia
Blood·2023Open Access
Supplementary Figure 1 from Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase &lt;i&gt;In vivo&lt;/i&gt;
2023Open Access
Supplementary Figure 1 from Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase &lt;i&gt;In vivo&lt;/i&gt;
2023Open Access
Data from Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase &lt;i&gt;In vivo&lt;/i&gt;
2023Open Access
Data from Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase &lt;i&gt;In vivo&lt;/i&gt;
2023Open Access
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Cancer Cell·2011· 403 citedOpen Access
Abstract C181: Preclinical efficacy and pharmacodynamics of SCH 900105 (AV-299) an anti-HGF antibody in an intracranial glioblastoma model
Molecular Cancer Therapeutics·2009· 9 cited
SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models
Cancer Research·2008· 1 cited
Role of the TGF-β/Alk5 Signaling Pathway in Monocrotaline-induced Pulmonary Hypertension
American Journal of Respiratory and Critical Care Medicine·2008· 141 citedOpen Access
Inhibition of p38α Mitogen-Activated Protein Kinase Prevents the Development of Osteolytic Bone Disease, Reduces Tumor Burden, and Increases Survival in Murine Models of Multiple Myeloma
Cancer Research·2007· 42 citedOpen Access
Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.
Blood·2006· 7 cited
Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase <i>In vivo</i>
Clinical Cancer Research·2006· 152 cited
SCIO-469, a Potent and Selective Inhibitor of p38a MAPK, Normalizes the Bone Marrow Microenvironment and Inhibits Multiple Myeloma Cell Proliferation in In Vitro and In Vivo Models.
Blood·2004· 2 cited
Inhibition of p38 MAP kinase activity enhances axonal regeneration
Experimental Neurology·2003· 87 cited
page 1 of 2Next →

Frequent Co-authors

Andy Protter(7), Alison Murphy(6), Rongrong Ge(5), Vaishali Rajeev(5), Partha Ray(5), Edmund C. Lattime(5), Susan R. Rittling(5), Jit Chakravarty(5), Sundeep Dugar(5), George F. Schreiner(5), Nicola Barnard(5), Guru Reddy(5), Linda S. Higgins(4), Michael Reiß(4), Andrew A. Protter(3), Partha Neogi(3), Maya S. Gowri(3), Gerald M. Reaven(3), Shalabh Gupta(3), Shalabh Gupta(3)